Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating staphylococcus aureus infection

A staphylococcus, golden technology, applied in the direction of chemical instruments and methods, antibacterial drugs, pharmaceutical formulations, etc.

Inactive Publication Date: 2008-02-13
NABI BIOPHARMLS
View PDF12 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, such IGIV compositions have not been shown to be effective in treating pre-existing S. aureus infections to date

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0082] Specific IGIV prevents MRSA S. aureus infection in mice

[0083] Hyperimmune-specific IGIV (AltaStaph TM ) ability to protect against Staphylococcus aureus infection. 15 mice were treated with AltaStaph TMimmunity. Alta Staph TM The dose contained 400 μg of specific antibody (9.6 mg total IgG / mouse). As a control, another group of 15 mice received 9.6 mg of muco-exopolysaccharide (MEP) IGIV containing approximately 15 μg of type 5-specific IgG. Low level amounts of type 5 specific IgG were about the same as seen in standard "non-specific" IGIV from commercial sources. Group 3 mice received 0.5 ml buffered saline. In addition, all mice received 0.5 ml of saline intraperitoneally 24 hours before challenge. It was demonstrated that this pre-challenge treatment of bacteria reduces mortality after challenge by bacterial exposure.

[0084] 2 x 10 in 5% mucin with three different 5 Colony forming units (CFU) of Staphylococcus aureus were challenged intraperitoneally...

example 2

[0088] Treatment of S. aureus bacteremia in humans using specific IGIV

[0089] In designed to evaluate AltaStaph TM The safety and use of hyperimmune specificity was studied in a double-blind placebo-controlled randomized trial in 40 patients with persistent S. aureus bloodstream infection (bacteremia) measuring S. aureus-specific antibody levels. IGIV for Staphylococcus aureus infection. Patients were randomly assigned to receive two doses of AltaStaph TM Or saline placebo administered intravenously in combination with standard of care treatment including treatment with antibiotics. The results of the study confirm that AltaStaph TM It was well tolerated and no drug-related serious adverse outcomes were reported. Via AltaStaph TM Treated patients were able to maintain antibody titers at protection from Staphylococcus aureus infection previously estimated by Shinefield et al. N.ENG.J.Med. 14:491-96 (2002) in patients with end-stage renal disease (ESRD) on and above sa...

example 3

[0111] Production of monoclonal antibodies against Staphylococcus aureus 336

[0112] A. Generation of immune splenocytes

[0113] S. aureus 336 polysaccharide antigen (native O-acetylated form or modified de-O-acetylated form) conjugated to recombinant extracellular protein A (S. aureus 336-rEPA) in combination with Freund's adjuvant (Freund' sadjuvants) immunized groups of 3 BALB / c female mice. Spleen cells were collected as a pool from mice that had been immunized three times at intervals of 2 weeks, and blood was drawn every other week for testing serum antibody titers. Splenocytes were prepared in 3 aliquots which were used immediately for fusion experiments or stored in liquid nitrogen for future fusion.

[0114] B. Generation of hybridomas

[0115] Fusion experiments were performed according to the procedure of Stewart and Fuller, J. Immunol. Methods 123:45-53 (1989). Supernatants from wells with growing hybrids were screened for monoclonal antibody (MAb) secretor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method of preventing or treating bacteremia caused by Staphylococcus aureus, said method comprising administering a drug comprising a drug specific for one or more Staphylococcus aureus (S. aureus) antigens. Monoclonal or polyclonal antibody compositions of the antibodies. In a specific embodiment, the composition is a hyperimmune specific IGIV composition. In another specific embodiment, the composition comprises antibodies to capsular polysaccharide S. aureus antigens, such as type 5 and / or type 8 antigens. In another embodiment, the composition comprises a monoclonal antibody directed against a capsular polysaccharide S. aureus antigen. The method provides an effective means of preventing or treating S. aureus bacteremia, and it can be used alone or in combination with other therapies.

Description

[0001] This application claims the benefit of US Patent Application Serial No. 60 / 642,093, filed January 10, 2005, which is hereby incorporated by reference in its entirety. technical field [0002] none Background technique [0003] Staphylococcus aureus infection is an important cause of disease and death, accounting for approximately 20% of all bacteremia cases. Staphylococcus aureus is the most common cause of hospital-acquired infections and is becoming increasingly resistant to antibiotics. In the United States alone, an estimated 12 million patients are at risk of acquiring S. aureus infection each year. Staphylococcus aureus is the leading cause of hospital-acquired bloodstream infections in 7,000 acute care hospitals in the United States and is becoming increasingly resistant to antibiotics, making the infections a powerful cause of illness and death, The crude mortality rate is about 25%. A study by Ruben et al., Emerg. Infect. Dis. 5: 9-17 (1999) showed that th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/085A61K39/02A61K39/00
CPCA61K38/4886A61K2039/545C07K16/1271A61K38/193A61K31/716A61K2039/505A61K38/48A61K45/06A61P31/04A61K2300/00A61K39/085A61K39/395
Inventor 加里·霍维特阿里·易卜拉欣·法汤姆
Owner NABI BIOPHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com